AI Terminal
Xbrane Biopharma
Declaration of Voting Results & Voting Rights Announcements • Jun 30, 2022
3128_rns_2022-06-30_a2fca4d6-f006-4e9a-93e4-092b2813c935.pdf
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
Xbrane Biopharma AB ("Xbrane" or the "Company") announces changes to the number of shares and votes in the Company.
The number of shares and votes in Xbrane have changed following the issue of 105,000 shares during June through exercise of warrants under LTIP 2019, adopted at the annual general meeting 2019.
As of June 30, 2022, the total number of shares and votes in the Company amounts to 25,144,906. The Company's registered share capital amounts to SEK 5,637,137.439365.
Contacts
Martin Åmark, CEO M: +46 76 309 37 77 E: [email protected]
Anette Lindqvist, CFO/IR M: +46 76 325 60 90 E: [email protected]
About Us
Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting SEK 332 billion in annual sales of the respective reference products, with the leading one under registration in Europe. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com
This information is information that Xbrane Biopharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2022-06-30 12:00 CEST.
Attachments
Xbrane Biopharma AB ("Xbrane" or the "Company") announces changes to the number of shares and votes in the Company.